Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Autonomix Medical, Inc. Common Stock

AMIX

Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.04 – $1.20
Volume 92,933
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.25M
Price / earnings
—
Price / book
0.32×
Price / sales
—
EV / sales
—
EV / EBITDA
0.45×

Profitability

Earnings per share
-$5.76
Return on assets
-143.76%
Return on equity
-169.73%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.52×
Quick ratio
6.52×
Cash ratio
6.13×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.04M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AMIX, quarterly periods
Line itemQ2 FY2027 Sep 30, 2026Q1 FY2027 Jun 30, 2026Q4 FY2026 Mar 31, 2026Q3 FY2026 Dec 31, 2025Q2 FY2026 Sep 30, 2025Q1 FY2026 Jun 30, 2025Q4 FY2025 Mar 31, 2025Q3 FY2025 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.59M$1.26M$1.28M$1.62M$5.17M$1.83M$1.7M$1.7M
Research and development$1.58M$1.52M$1.46M$1.72M$2.37M$1.59M$1.55M$1.04M
Total operating expenses$3.18M$2.77M$2.74M$3.34M$7.53M$3.42M$3.25M$2.75M
Operating income-$3.18M-$2.77M-$2.74M-$3.34M-$7.53M-$3.42M-$3.25M-$2.75M
Interest expense$0$0$0$0$0$0-$46K-$45K
Income before taxes-$3.13M-$2.73M-$2.67M-$3.26M-$7.45M-$3.34M-$3.19M-$2.71M
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.13M-$2.73M-$2.67M-$3.26M-$7.45M-$3.34M-$3.19M-$2.71M
Net income attributable to common shareholders-$3.13M-$2.73M-$2.67M-$3.26M-$7.45M-$3.34M-$3.19M-$2.71M
EBITDA-$3.17M-$2.77M-$2.73M-$3.34M-$7.53M-$3.42M-$3.2M-$2.7M
Basic earnings per share-$2.51-$5.02-$4.90-$7.56-$29.02-$22.69-$24.33-$30.66
Diluted earnings per share-$2.51-$5.02-$4.90-$7.56-$29.02-$22.69-$24.33-$30.66

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

Autonomix Medical announced a warrant inducement agreement with an investor to exercise outstanding July 2026 Warrants for 857,462 shares at $5.75 per share, generating approximately $4.9 million in gross proceeds. In exchange, the company issued new Series E-1 and E-2 warrants to purchase 535,913 shares each at $6.25 per share. The transaction is expected to close on August 26, 2026.

GlobeNewswire Inc.

Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study

Autonomix Medical announced positive preclinical study results showing its neural sensing platform can detect, localize, and confirm changes in renal neural activity. The technology enables physiological feedback during renal denervation procedures, potentially addressing current limitations where physicians rely on anatomical landmarks rather than direct neural information. The company plans further preclinical and clinical studies to evaluate physiology-guided renal denervation applications.

GlobeNewswire Inc.

Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

Autonomix Medical announced a warrant inducement agreement where an investor will exercise outstanding warrants to purchase 428,731 shares at $6.00 per share, generating approximately $2.6 million in gross proceeds. In return, the company will issue new Series D-1 and D-2 warrants with a $5.75 exercise price. The transaction is expected to close on or about July 15, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 24, 20261-for-21reverse split
Oct 25, 20241-for-20reverse split